Home
Catalog
Cagrilintide

PEPTAURA

Home
Catalog
Cagrilintide

Home Catalog Suppliers COAs Shipping Verify

Site Map

Home Catalog RFQ FAQ Verify Suppliers COAs Become an Affiliate Sellers Portal Contact

Legal

Disclaimers Privacy Policy

© 2026 peptaura.com, All Rights Reserved.

CAGRILINTIDE

Dose per Vial/Pen

Latest Research

In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research.

Alhalabi H, Borschel L, Le Foll C, Thomas A, Bally L, Thevis M

Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.

Lempesis IG, Dalamaga M

Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro.

Old V, Davies M, Denniff M, Choudhary P, Eastley N, Ashford RU, Watson E

Childhood Obesity and Cardiac Risk in Youth: Emerging Challenges Toward 2050.

Mishra NK

New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.

Pardali EC, Gkouskou KK, Cholevas C, Poulimeneas D, Tsiroukidou K, Goulis DG, Grammatikopoulou MG

Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.

Ahmed M, Hassan M, Tahir M, Hussain M, Islam F, Khan GT, Ahsan M, Bin Shafiq S, Ibrahim A, Uddin A, Waqas SA

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.

Bailey CJ, Flatt PR, Conlon JM

Bariatric Surgery in the Era of GLP1RA: A Narrative Review.

Muhundan M, Dash S

CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.

Gadelmawla AF, Hammad N, Atta K, Diaa A, Abouzkaly F, Soni K, Kelkar R, Agrawal SP, Ahmed R, Jain H, Passey S, Aronow WS

Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.

Chung CW, Kim J